Company Overview of Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases. The company’s lead product candidate is an oral pharmaceutical-grade L-glutamine, which has completed Phase III clinical trials for the treatment of sickle cell anemia and sickle ß0-thalassemia. It also markets and sells NutreStore L-glutamine powder for oral solution as a treatment for short bowel syndrome in patients receiving specialized nutritional support; and sells L-glutamine as a nutritional supplement under the AminoPure brand name through retail stores in various states, as well as through importers and distributors in Japan, Ta...
21250 Hawthorne Boulevard
Torrance, CA 90503
Founded in 2000
Key Executives for Emmaus Life Sciences, Inc.
Chief Financial Officer and Principal Accounting Officer
Chief Operating Officer and Director
Senior Vice President of Finance
Senior Vice President of Research and Development
Chief Administrative Officer and Corporate Secretary
Compensation as of Fiscal Year 2015.
Emmaus Life Sciences, Inc. Key Developments
Emmaus Life Sciences, Inc. announced delayed 10-Q filing
Aug 17 15
On 08/17/2015, Emmaus Life Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Emmaus Life Sciences, Inc. Announces Resignation of Henry A. Mckinnell as Board of Directors, Effective from August 19, 2015
Aug 14 15
On August 10, 2015, Henry A. McKinnell, Jr., member of the Board of Directors of Emmaus Life Sciences, Inc. tendered his resignation from the Board, effective as of close of business on August 14, 2015 which has subsequently been extended to August 19, 2015. Prior to his resignation, Dr. McKinnell was a member of the Board's Audit and Compensation, Nominating and Corporate Governance Committees.
Emmaus Life Sciences, Inc. Announces Board Changes
Aug 7 15
On August 3, 2015, the Board of Emmaus Life Sciences, Inc. appointed Scott Gottlieb, MD to serve as a director of the company, effective immediately. Dr. Gottlieb was not appointed as a member of any board of directors committees in connection with his appointment, although the Board is continuing to evaluate whether Dr. Gottlieb may be appointed to a board committee in the future. Dr. Gottlieb was selected as a director pursuant to that certain agreement, dated as of September 11, 2013, pursuant to which T.R. Winston & Company, LLC has the right to designate a member of the Board. Dr. Gottlieb has been a Managing Director at TRW since 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 13, 2015